COPENHAGEN, Sept 7 (Reuters) – Novo Nordisk said on Monday that in a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide, the active ingredient in its blockbuster
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Tech companies look to Argentina’s windswept Patagonia to build massive data centers
By Leila Miller BUENOS AIRES, Sept 7 (Reuters) - Argentina's rugged Patagonia is drawing increasing…
Audi introduces new compact EV in bid to boost European sales
By Gilles Guillaume PARIS, Sept 7 (Reuters) - Premium German car brand Audi on Monday…
Galvan double guides River Plate to 3-1 win over Independiente Rivadavia
VIDEO SHOWS: HIGHLIGHTS OF ROUND 8 OF THE CLAUSURA TOURNAMENT GAME BETWEEN RIVER PLATE AND…
